Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ampicillin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ampicillin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ampicillin sodium -

Canada - English - Health Canada

auro pharma inc - ampicillin (ampicillin sodium) - powder for solution - 250mg - ampicillin (ampicillin sodium) 250mg - aminopenicillins

Canada - English - Health Canada

auro pharma inc - ampicillin (ampicillin sodium) - powder for solution - 500mg - ampicillin (ampicillin sodium) 500mg - aminopenicillins

Canada - English - Health Canada

auro pharma inc - ampicillin (ampicillin sodium) - powder for solution - 1g - ampicillin (ampicillin sodium) 1g - aminopenicillins

Canada - English - Health Canada

auro pharma inc - ampicillin (ampicillin sodium) - powder for solution - 2g - ampicillin (ampicillin sodium) 2g - aminopenicillins

United States - English - NLM (National Library of Medicine)

auromedics pharma llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp.,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients (see precautions–pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae * ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli ,* and bacteroides spp.* (including b. fragilis * ). *  efficacy for this organism in this organ system was studie

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli* , klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis* , bacteroides fragilis* , enterobacter spp.*, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients see precautions, pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli* , and bacteroides spp.* (including b. fragilis* ). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicilli

United States - English - NLM (National Library of Medicine)

eugia us llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp.* (including k. pneumoniae * ), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp.,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients (see precautions–pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae * ), bacteroides spp. (including b. fragilis ), and enterobacter spp.*  gynecological infections caused by beta-lactamase producing strains of escherichia coli ,* and bacteroides spp.* (including b. fragilis * ). *  efficacy for this organism in this organ system was studied in